Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr.

Read More

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

Oral presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
  • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
  • Presenter: Joely Kaufman, MD
  • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October
    Read More

    Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting | Nachricht

    IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ –Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

    The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

    Oral presentations include:

    • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
    • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
    • Presenter: Joely Kaufman, MD
    • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11
    Read More

    Castle Biosciences to Present Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

    Oral presentations to highlight both commercially available skin cancer prognostic tests

    Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020.

    Presentation details are as follows:

    Title: Clinical validation and incorporation of a prognostic 40-gene expression profile test into clinicopathological risk assessment for cutaneous squamous cell carcinoma (cSCC)
    Session: Skin Cancer & Reconstruction
    Presenter: Sherrif Ibrahim M.D., Ph.D., associate professor, University of Rochester Medical Center
    Date: Friday, October 9, 2020
    Time: 6:24 p.m. – 6:27 p.m. ET

    Title: Cutaneous melanoma prognostic model combining 31-gene expression profile and sentinel lymph node biopsy
    Session: Skin Cancer & Reconstruction
    Presenter: Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas
    Date: Friday, October 9, 2020
    Time: 6:30 p.m. –

    Read More

    Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting

    HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

    The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

    ————————
    Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
    ————————

    About Soliton, Inc.

    Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center.

    Read More

    Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting | News

    HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

    The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

    ————————
    Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
    ————————

    About Soliton, Inc.

    Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The

    Read More

    Soliton to Present Poster on Pivotal Cellulite Data at Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting | Nachricht

    HOUSTON, Oct. 5, 2020 /PRNewswire/ — Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary aesthetic platform technology, today announced the Company has been accepted to present its pivotal cellulite data via an online poster during the Virtual American Society for Dermatologic Surgery (ASDS) 2020 Annual Meeting, taking place October 9-11, 2020.

    The poster presentation titled, “Improvement in the Appearance of Cellulite Depressions and Skin Laxity Resulting from a Single Treatment with Acoustic Subcision: Findings from a Multi-Center Pivotal Trial”, will be available to registered attendees beginning October 9, 2020 at 8:00 a.m. ET.

    ————————
    Join our more than 200K subscribers here to follow the Company: https://soly-investors.com
    ————————

    About Soliton, Inc.

    Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of MD Anderson Cancer Center. The

    Read More